Geode Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-360,738
| Closed | -$1.77M | – | 5028 |
|
|
2021
Q3 | $1.77M | Buy |
360,738
+25,632
| +8% | +$124K | ﹤0.01% | 3408 |
|
|
2021
Q2 | $1.77M | Buy |
335,106
+46,831
| +16% | +$242K | ﹤0.01% | 3319 |
|
|
2021
Q1 | $1.38M | Buy |
288,275
+130,162
| +82% | +$680K | ﹤0.01% | 3425 |
|
|
2020
Q4 | $684K | Buy |
158,113
+468
| +0.3% | +$2K | ﹤0.01% | 3492 |
|
|
2020
Q3 | $649K | Hold |
157,645
| – | – | ﹤0.01% | 3354 |
|
|
2020
Q2 | $403K | Sell |
157,645
-138,287
| -47% | -$406K | ﹤0.01% | 3439 |
|
|
2020
Q1 | $855K | Sell |
295,932
-4,525
| -2% | -$20.3K | ﹤0.01% | 3078 |
|
|
2019
Q4 | $1.14M | Buy |
300,457
+33,902
| +13% | +$162K | ﹤0.01% | 3232 |
|
|
2019
Q3 | $1.36M | Buy |
266,555
+1,686
| +0.6% | +$10.4K | ﹤0.01% | 3120 |
|
|
2019
Q2 | $1.64M | Buy |
264,869
+23,076
| +10% | +$133K | ﹤0.01% | 3058 |
|
|
2019
Q1 | $1.72M | Buy |
241,793
+8,893
| +4% | +$80K | ﹤0.01% | 2938 |
|
|
2018
Q4 | $1.99M | Buy |
232,900
+14,902
| +7% | +$194K | ﹤0.01% | 2777 |
|
|
2018
Q3 | $4.36M | Buy |
217,998
+19,104
| +10% | +$449K | ﹤0.01% | 2438 |
|
|
2018
Q2 | $5.14M | Buy |
198,894
+27,191
| +16% | +$753K | ﹤0.01% | 2305 |
|
|
2018
Q1 | $4.1M | Buy |
171,703
+27,089
| +19% | +$854K | ﹤0.01% | 2366 |
|
|
2017
Q4 | $4.9M | Buy |
144,614
+17,570
| +14% | +$491K | ﹤0.01% | 2227 |
|
|
2017
Q3 | $2.69M | Buy |
127,044
+690
| +0.5% | +$12.6K | ﹤0.01% | 2577 |
|
|
2017
Q2 | $2.21M | Buy |
126,354
+561
| +0.4% | +$9.28K | ﹤0.01% | 2676 |
|
|
2017
Q1 | $2.2M | Buy |
125,793
+5,920
| +5% | +$101K | ﹤0.01% | 2615 |
|
|
2016
Q4 | $2.02M | Buy |
119,873
+5,242
| +5% | +$81.1K | ﹤0.01% | 2618 |
|
|
2016
Q3 | $1.88M | Buy |
114,631
+2,430
| +2% | +$36.9K | ﹤0.01% | 2595 |
|
|
2016
Q2 | $1.7M | Buy |
112,201
+22,733
| +25% | +$375K | ﹤0.01% | 2581 |
|
|
2016
Q1 | $1.29K | Buy |
89,468
+14,633
| +20% | +$246K | ﹤0.01% | 2747 |
|
|
2015
Q4 | $2.12M | Buy |
74,835
+23,349
| +45% | +$393K | ﹤0.01% | 2439 |
|
|
2015
Q3 | $861K | Buy |
51,486
+2,363
| +5% | +$53.8K | ﹤0.01% | 2951 |
|
|
2015
Q2 | $1.29M | Buy |
49,123
+6,804
| +16% | +$132K | ﹤0.01% | 2770 |
|
|
2015
Q1 | $740K | Buy |
42,319
+2,845
| +7% | +$48.8K | ﹤0.01% | 3018 |
|
|
2014
Q4 | $685K | Buy |
39,474
+21,877
| +124% | +$332K | ﹤0.01% | 3037 |
|
|
2014
Q3 | $327K | Buy |
17,597
+146
| +0.8% | +$2.51K | ﹤0.01% | 3360 |
|
|
2014
Q2 | $319K | Buy |
+17,451
| New | +$313K | ﹤0.01% | 3353 |
|
Geode Capital Management's ADMS Position: Q4 2021 in Review
Geode Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 360,738 shares — an estimated $1.77M sold.
Geode Capital Management first reported a position in ADMS in Q2 2014 and held it in 30 quarters. The position peaked at $5.14M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Geode Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Geode Capital Management sold 360,738 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1.77M.
- Geode Capital Management first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- Geode Capital Management's Adamas Pharmaceuticals position peaked at $5.14M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Geode Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.